MedTrace Logo

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

NCT00289588 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2006-02-16

No results posted yet for this study

Summary

The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.

Conditions

  • Community-Acquired MRSA Infections
  • Abscesses
  • Cellulitis
  • Folliculitis

Interventions

DRUG

Mupirocin (drug)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Becton, Dickinson and Company

    collaborator INDUSTRY

  • Brooke Army Medical Center

    lead FED

Principal Investigators

  • Michael W Ellis, MD · Brooke Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00289588 on ClinicalTrials.gov